Dassault Systèmes announced the launch of three industry solution experiences for life sciences, focused on BioPharma. “ONE Lab,” “Designed to Cure” and “Made to Cure for BioPharma” complement the existing “License to Cure for BioPharma.” Pharmaceutical and biotechnology companies now have access to an end-to-end, holistic approach to digitally transform the complex processes behind the design, development and production of novel therapeutics.
Today’s life sciences industry is plagued by challenges at every stage of therapeutics development including cost pressures and long cycle times that leave little room for innovation. Research and development expenditures exceed those of the aerospace and automotive industries combined, yet the success rate of new drug development from its initial concept phase is less than one percent. This risk is compounded by patent expirations, global competition, strict regulatory requirements, a deluge of scientific data and operations - both within the enterprise and with outsourced partners - working in silos.
Dassault Systèmes’ industry solution experiences for pharmaceutical and biotechnology companies introduce a single digital environment to streamline the scientific and operational processes involved in therapeutics innovation. They allow for biological and chemical modeling and simulation, open collaborative discovery and research, unified laboratory management, efficient production processes and integrated quality and regulatory management. These are all critical capabilities for developing advanced pipelines and bringing effective patient therapies to market faster and at lower costs.
Together, these industry solution experiences provide digital continuity to help companies accelerate and improve therapeutics discovery, development, approval, production and patient adoption:
“ONE Lab” integrates people, resources, processes, data, analysis and documentation so that laboratories can leverage knowledge and more efficiently collaborate on researching, developing and testing products.
“Made to Cure for BioPharma” leverages process and quality data and knowledge across multiple organizations and geographies, optimizing processes and products and reducing process development times and technology transfer costs.
“Designed to Cure” uses collaboration, common knowledge, predictive analytics and virtual design and simulation to model and identify higher quality candidates earlier in the process.
“License to Cure for BioPharma,” first launched in 2014, ensures regulatory compliance and high quality process management.
“Dassault Systèmes’ industry solution experiences for life sciences leverage the same 3DEXPERIENCE universes that have long been used by the industrial engineering world to enhance consumer experiences,” said Jean Colombel, Vice President Life Sciences Industry, Dassault Systèmes. “In life sciences, we focus on the patient experience. With a digital environment, companies can maximize return on investment, accelerate decision making, bring advanced solutions to market faster and potentially change lives.”
